Welichem Biotech Inc.   Report issue

For profit Phase 2
Founded: Burnaby Canada (2004)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2008
NCT00837551
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Welichem Biotech Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

benvitimod (3 trials)

gemcitabine (gemzar) (1 trial)

slc-0111 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Neoplasms (Phase 1)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3